Sight Sciences (SGHT) Q2 FY26 earnings call

Sight Sciences delivered a strong second quarter, marked by significant revenue growth across both interventional segments and improved operating results. The company raised its full-year revenue guidance and lowered its adjusted operating expense outlook, demonstrating a balanced approach to growth and financial discipline. Management highlighted the strategic advantage of addressing both glaucoma and dry eye disease in the same patient population and clinical workflows, while preparing for the launch of OmniUltra and navigating ongoing payer engagement for TierCare.